Effects of Early and Late Time-restricted Eating on Overweight Adults With Metabolic Syndrome
Study Details
Study Description
Brief Summary
Investigators aim to compare the effects of early and late time-restricted feeding on overweight adults with metabolic syndrome
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Early time-restricted eating (eTRE) The eTRE group is instructed to consume all calories from 7 AM to 3 PM each day and fast from 3 PM to 7 AM |
Behavioral: Early time-restricted eating (eTRE)
The eTRE group is instructed to consume all calories in early 8h eating window,
|
| Experimental: Late time-restricted eating (lTRE) The lTRE group is instructed toconsume all calories from 11 AM to 7 PM each day and fast from 7 PM to 11 PM |
Behavioral: Late time-restricted eating (lTRE)
The lTRE group is instructed to consume all calories in late 8h eating window.
|
Outcome Measures
Primary Outcome Measures
- Changes in body weight [0-week; 6-week and 12-week]
Body weight is assessed at the research center with the participants without shoes and in light clothing using a digital scale (OMRON MEDICAL Beijing Co., Ltd. HNH-318) to the nearest 0.1 kg.
- Changes in abdominal fat area [0-week; 6-week and 12-week]
Abdominal fat area is measured using bioelectrical impedance analysis (OMRON MEDICAL Beijing Co., Ltd. DUALSCAN, HDS-2000) to the nearest 1 cm2.
Secondary Outcome Measures
- Changes in body composition ( body fat mass) [0-week; 6-week and 12-week]
Body composition (body fat mass ) is measured using the direct segmental multifrequency bioelectrical impedance analysis method DSM-BIA (InBody H20) to the nearest 0.1 kg.
- Changes in body composition (body muscle mass) [0-week; 6-week and 12-week]
Body composition ( body muscle mass) is measured using the direct segmental multifrequency bioelectrical impedance analysis method DSM-BIA (InBody H20) to the nearest 0.1 kg.
- Changes in glycemic control, haemoglobin A1c (HbA1c) [0-week; 6-week and 12-week]
HbA1c is measured on an automatic HbA1c analyzer (TOSOH BIOSCIENCE, Inc.; HLC-723G8) to the nearest 0.1%.
- Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) [0-week; 6-week and 12-week]
Plasma lipids of total cholesterol, TG, HDL-c, and LDL-c are measured on an automatic biochemistry analyzer (HITACHI, Inc.; LAbOSPECT, 008AS) using standard reagents to the nearest 0.01 mmol/L.
- Changes in uric acid (UA) [0-week; 6-week and 12-week]
UA is measured on an automatic biochemistry analyzer (HITACHI, Inc.; LAbOSPECT, 008AS) using standard reagents to the nearest 1 µmol/L.
- Changes in blood pressure. [0-week; 6-week and 12-week]
Blood pressure is measured in triplicate using a digital automatic blood pressure (Omron HBP-9020, Kyoto, Japan) to the nearest 1 mmHg.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age from 18 to 65 years
-
Body mass index (BMI): 24.0-40.0 kg/m2
-
Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5):
-
Waist circumference ≥ 90 cm (men) or ≥ 80 cm (women).
-
Elevated triglyceride (TG) (use of medications for elevated TG is an alternate indicator) ≥ 150 mg/dL (1.7 mmol/L).
-
Reduced high-density lipoprotein cholesterol (HDL-c) (use of medications for reduced HDL-c is an alternate indicator) < 40 mg/dL (1.0 mmol/L) in males < 50 mg/dL (1.3 mmol/L) in females.
-
Elevated blood pressure (use of hypoglycemic medications is an alternate indicator). Systolic blood pressure (SBP) ≥ 130 and/or diastolic blood pressure (DBP) ≥ 85 mmHg.
-
Elevated fasting blood glucose (FBG) (used of hypoglycemic medications is an alternate indicator) ≥ 100 mg/dL (5.6 mmol/L).
Exclusion Criteria:
-
Unstable weight (change > 10% current body weight) for 3 months prior to the study
-
Pregnant or breast-feeding
-
Night shift workers
-
History of major diseases or related diseases, such as cancer, inflammatory disease, chronic obstructive pulmonary disease and major adverse cardiovascular event
-
Active viral hepatitis, acquired immune deficiency syndrome, syphilis and other sexually transmitted diseases, tuberculosis and other infectious diseases
-
Being treated with antibiotics or corticosteroids
-
Current participate in other weight-management program, current on a prescribed diet for special disease or current on any drugs that effect appetite
-
The researcher deemed it inappropriate to participate in the experimenter.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- First Affiliated Hospital Xi'an Jiaotong University
Investigators
- Study Chair: Bingyin Shi, First Affiliated Hospital Xi'an Jiaotong University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- No.XJTU1AF2023LSK-398